Register today for the Third Annual SOSV Climate Tech Summit

Fast and affordable enzyme development platform

GET CONNECTED
allozymes.com

Team

Peyman Salehian

CEO

Akbar Vahidi

CTO

Allozymes

Company details

Allozymes is building a platform to discover and scale novel enzymes powered by microfludics.

Bio-manufacturingClimate TechHuman HealthSingaporeSeedClimate TechHard TechHealthcareHuman HealthHAX 2019

Company News

GenScript, Allozymes Partner To Advance Enzyme Discovery And Development

December 8, 2022
Contract Pharma

CSM Ingredients and Allozymes in strategic tie-up on rapid novel enzyme development

September 22, 2022
foodnavigator.com

Just one droplet: Allozymes claims proprietary tech increases actives yields, boosts sustainability

September 8, 2022
cosmeticsdesign.com

Allozymes wants to supercharge manufacturing with engineered enzymes

July 7, 2021
CompassList

Allozymes looks to upend chemical manufacturing with rapid enzyme engineering and $5M seed

July 6, 2021
TechCrunch

Get In Touch with Allozymes

Please tell us a little bit about yourself and why you'd like to get connected. Allozymes + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden
Opt-in checkbox


We don’t spam. Our Privacy Policy and Terms of Use apply.
* If you are interested in investing directly into SOSV's portfolio of privately held companies, or into SOSV's funds, you need to meet the SEC’s criteria for accredited investor status. As an individual, you can qualify as an accredited investor by either (a) having more than $200,000 in annual income for each of the past two years (or $300,000 with your spouse) and a reasonable expectation of earning the same this year or (b) having a net worth of at least $1 million (not including your principal residence). Learn More